EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease

Rohit Loomba iD, Vincent Wai-Sun Wong iD

Alimentary Pharmacology & Therapeutics · 2024-01 · 59 (2) · 150-156

DOI: 10.1111/apt.17846 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Alimentary Pharmacology & Therapeutics, online erschienen am 28.12.2023. Verfasst von Rohit Loomba und 1 weiteren Autor:innen. Beteiligte Einrichtung: MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA. Hauptthemen laut MEDLINE: Non-alcoholic Fatty Liver Disease, Metabolic Diseases, Liver Diseases, Alcoholic. Die Arbeit wurde bisher 126-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, NIDDK NIH HHS, NIAAA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The American and European liver associations have endorsed new nomenclature of steatotic liver disease (SLD) and definition of metabolic dysfunction‐associated steatotic liver disease (MASLD).

Aims

To review the historical development leading to the changes and to discuss the implications of the changes on research and clinical practice Methods We performed a literature search using keywords related to MASLD and non‐alcoholic fatty liver disease (NAFLD).

Results

The SLD umbrella allows classification of patients under the key categories of MASLD, alcohol‐associated liver disease and a new entity termed MetALD, which represents MASLD with increased alcohol intake. The diagnosis of MASLD requires the demonstration of hepatic steatosis and at least one metabolic risk factor, whereas MASLD can co‐exist with other liver diseases such as chronic viral hepatitis. Despite the change in definition, over 95% of patients previously known as having NAFLD fulfil diagnostic criteria for MASLD. It is conceivable that future clinical trials and biomarker studies will continue to exclude concomitant liver diseases. As most patients with MASLD are seen at primary care and non‐hepatology settings, communication with other stakeholders is essential to ensure disease awareness and smooth adoption of the changes.

Conclusions

The new nomenclature is both a challenge, given the need for dissemination and education across the spectrum of stakeholders, and an opportunity to bring everyone together and spark new research to better understand epidemiology, natural history, diagnosis, biomarkers and management strategies across the spectrum of SLD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Non-alcoholic Fatty Liver DiseaseMetabolic DiseasesLiver Diseases, AlcoholicHumans

Autor:innen und Institutionen

  • MASLD Research Center, Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • Division of Gastroenterology and Hepatology, University of California at San Diego, La Jolla, California, USA.
  • School of Public Health, University of California at San Diego, La Jolla, California, USA.
  • Medical Data Analytic Centre, Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong, China.
  • State Key Laboratory of Digestive Disease, Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, China.

ORCID-Profile: Rohit Loomba, Vincent Wai-Sun Wong

Förderung

  • NCATS NIH HHS
  • NIDDK NIH HHS
  • NIAAA NIH HHS
  • NHLBI NIH HHS
  • National Institute on Alcohol Abuse and Alcoholism
  • Chinese University of Hong Kong
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Center for Advancing Translational Sciences

Zitieren

APA

Loomba, R., & Wong, V. W. (2024). Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease. Alimentary Pharmacology & Therapeutics, 59(2), 150-156. https://doi.org/10.1111/apt.17846

Vancouver

Loomba R, Wong VW. Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease. Alimentary Pharmacology & Therapeutics. 2024;59(2):150-156. doi:10.1111/apt.17846

BibTeX
@article{Loomba2024,
  author = {Loomba, Rohit and Wong, Vincent Wai-Sun},
  title = {Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction‐associated steatotic liver disease},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2024},
  volume = {59},
  number = {2},
  pages = {150--156},
  doi = {10.1111/apt.17846}
}
Kostenlos starten →